Axsome Therapeutics (AXSM) Operating Margin (2022 - 2025)
Historic Operating Margin for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to 26.97%.
- Axsome Therapeutics' Operating Margin rose 328100.0% to 26.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 37.85%, marking a year-over-year increase of 526300.0%. This contributed to the annual value of 72.74% for FY2024, which is 129300.0% up from last year.
- Latest data reveals that Axsome Therapeutics reported Operating Margin of 26.97% as of Q3 2025, which was up 328100.0% from 24.47% recorded in Q2 2025.
- In the past 5 years, Axsome Therapeutics' Operating Margin ranged from a high of 6.74% in Q1 2023 and a low of 444.23% during Q2 2022
- Over the past 4 years, Axsome Therapeutics' median Operating Margin value was 89.62% (recorded in 2024), while the average stood at 123.66%.
- As far as peak fluctuations go, Axsome Therapeutics' Operating Margin soared by 3049200bps in 2023, and later tumbled by -829600bps in 2024.
- Axsome Therapeutics' Operating Margin (Quarter) stood at 245.86% in 2022, then surged by 44bps to 137.39% in 2023, then surged by 55bps to 61.14% in 2024, then skyrocketed by 56bps to 26.97% in 2025.
- Its Operating Margin stands at 26.97% for Q3 2025, versus 24.47% for Q2 2025 and 46.91% for Q1 2025.